NEW YORK (GenomeWeb) – DermTech, a private developer of gene expression-based tests for skin diseases, announced today that it has formed a sales and marketing collaboration with Dermpath Diagnostics.
Under the terms of the deal, Dermpath — a Quest Diagnostics-owned dermatopathology services provider — will provide specialty dermatology representatives in up to 10 regional territories across the US to help DermTech in marketing its Pigmented Lesion assay (PLA), which analyzes the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions.
Additional terms of the arrangement were not disclosed.
"This collaboration will significantly expand our ability to offer the PLA to dermatologists in the US," Sarah Dennison, vice president of marketing at DermTech, said in a statement.
Michael Kramer, vice president of dermatopathology at Dermpath, added, "We are pleased to align with DermTech in offering their innovative PLA and to further our mission to provide comprehensive dermatopathology services to the medical community."